EP1891052A1 - Inhibiteur de tubuline et sa methode de preparation - Google Patents

Inhibiteur de tubuline et sa methode de preparation

Info

Publication number
EP1891052A1
EP1891052A1 EP06784720A EP06784720A EP1891052A1 EP 1891052 A1 EP1891052 A1 EP 1891052A1 EP 06784720 A EP06784720 A EP 06784720A EP 06784720 A EP06784720 A EP 06784720A EP 1891052 A1 EP1891052 A1 EP 1891052A1
Authority
EP
European Patent Office
Prior art keywords
trifluoro
pyrazin
process according
amine
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06784720A
Other languages
German (de)
English (en)
Inventor
David Michael Blum
Yanzhong Wu
Jean Schmid
Timothy John Doyle
Jay Thomas Afragola
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37074929&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP1891052(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth LLC filed Critical Wyeth LLC
Publication of EP1891052A1 publication Critical patent/EP1891052A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to a 5-[(trisubstituted)phenyl]-pyrazinylpyrimidine compound which is a tubulin inhibitor useful in the treatment of cancer and a process for its preparation.
  • Antimicrotubule drugs are a major category of anticancer agents (Rowinsky, E.K., and Tolcher, A.W. Antimicrotubule agents. In: VT. Devita, Jr., S. Hellman, and S.A. Rosenberg (eds.), Cancer Principles and Practice, Ed. 6, pp. 431-452. Philadelphia: Lippincott Williams and Wilkins, 2001 ).
  • Antimicrotubule drugs work by interfering with the function of cellular microtubules, particularly the mitotic spindle. The disruption of normal spindle function leads to apoptotic cell death.
  • microbicidal active substances are disclosed in US 2003/0092718 A1.
  • the present invention overcomes the disadvantage of the hygroscopicity of the hydrochloride salt.
  • the present invention is based upon the unexpected discovery that the selection of the hemifumarate salt of 6-chloro-5- ⁇ 2,6-difluoro-4-[3-(methylamino)propoxy]phenyl ⁇ - 2-pyrazin-2-yl-N-[(1 S)-2,2,2-trifluoro-1 -methylethyl]pyrimidin-4-amine essentially avoids the disadvantage of the hygroscopic character associated with the hydrochloride.
  • the present invention in one embodiment concerns 6-chloro-5- ⁇ 2,6-difluoro-4-[3- (methylamino)propoxy]phenyl ⁇ -2-pyrazin-2-yl-N-[(1 S)-2,2,2-trifluoro-1 - methylethyl]pyrimidin-4-amine hemifumarate.
  • the invention also concerns a process for the preparation of 6-chloro-5- ⁇ 2,6-difluoro-4-[3-(methylamino)propoxy]phenyl ⁇ -2-pyrazin-2-yl-N-[(1S)- 2,2,2-trifluoro-1 -methylethyl]pyrimidin-4-arnine hemifumarate; which process comprises the steps of:
  • R 1 and R 2 are independently C 1 -C 3 alkyl in an aprotic solvent in the presence of a base and acidifying to obtain 2-pyrazin-2-yl-5-(2,4,6-trifluoro-phenyl)-pyrimidine- 4,6-diol of the formula
  • 6-Chloro-5- ⁇ 2,6-difluoro-4-[3-(methylamino)propoxy]phenyl ⁇ -2-pyrazin-2-yl-N-[(1S)- 2,2,2-trifluoro-1-methylethyl]pyrimidin-4-amine may also be called S- ⁇ 6-chloro-5-[2,6- difluoro-4-(3-methylamino-propoxy)-phenyl]-2-pyrazin-2-yl-pyrimidin-4-yl ⁇ -(2,2,2- trifluoro-1 -methyl-ethyl)-amine.
  • an embodiment of the invention is a process for the preparation of 6- chloro-5- ⁇ 2,6-difluoro-4-[3-(methylamino)propoxy]phenyl ⁇ -2-pyrazin-2-yI-N-[(1S)- 2,2,2-trifluoro-1 -methylethyl]pyrimidin-4-amine hemifumarate
  • a particular embodiment of the invention is a process for the preparation of 6-chloro- 5- ⁇ 2,6-difluoro-4-[3-(methylamino)propoxy]phenyl ⁇ -2-pyrazin-2-yl-N-[(1S)-2,2,2- trifluoro-1-methylethyl]pyrimidin-4-amine hemifumarate which process comprises the steps of:
  • the ratio of ethyl acetate to ethyl alcohol is 1 :1 V/V.
  • the absolute configuration of any compound including the compound of this invention may be determined by conventional X-ray crystallography.
  • the present invention provides 6-chloro-5- ⁇ 2,6-difluoro-4-[3- (methylamino)propoxy]phenyl ⁇ -2-pyrazin-2-yl-N-[(1 S)-2,2,2-trif luoro-1 - methylethyl]pyrimidin-4-amine hemifumarate which is useful in cancer treatment and methods for synthesizing said hemifumarate.
  • the present invention provides a method of treating or inhibiting the growth of cancerous tumor cells and associated diseases in a mammal by administering an effective amount of 6-chloro-5- ⁇ 2,6-difluoro-4-[3-(methylamino)propoxy]phenyl ⁇ -2- pyrazin-2-yl-N-[(1 S)-2,2,2-trifluoro-1 -methylethyI]pyrimidin-4-amine hemifumarate.
  • the present invention further provides a pharmaceutical composition which comprises an effective amount of 6-chloro-5- ⁇ 2,6-difluoro-4-[3-
  • the invention further provides the compound 6-chloro-5- ⁇ 2,6-difluoro-4-[3- (methylamino)propoxy]phenyl ⁇ -2-pyrazin-2-yl-N-[(1S)-2,2,2-trifluoro-1- methylethyl]pyrimidin-4-amine hemifumarate produced by the process which comprises:
  • alkyl means a straight or branched alkyl of 1 to 3 carbon atoms.
  • Halogenating agent means the chlorinating agent, phosphorus oxychloride
  • Aprotic solvents include N,N-dimethylformamide, 1-methyl-2-pyrrolidinone and diglyme.
  • aprotic solvents further include tetrahydrofuran (THF) or toluene.
  • aprotic solvents include toluene and ethyl acetate.
  • Alkali metal hydride includes lithium, potassium or sodium hydride.
  • Alkali metal alkoxide includes lithium, potassium or sodium alkoxide.
  • alkali metal alkoxide includes potassium t-butoxide.
  • Alcohol includes methyl, ethyl and isopropyl alcohols.
  • a base is selected from an alkali metal hydroxide, alkali metal carbonate, and an alkali metal hydride.
  • the alkali metal carbonate is sodium or potassium carbonate.
  • a preferred embodiment is potassium carbonate.
  • Base A is an alkali metal alkoxide or alkali metal hydroxide.
  • Base B is an alkali metal alkoxide or an alkali metal hydride.
  • an alkali metal alkoxide is preferably potassium t- butoxide and an alkali metal hydride is preferably sodium hydride.
  • An amine base is selected from 1 ,8-diazabicyclo[4.3.0]non-5-ene(DBU), N 1 N- diisopropylethylamine, tributylamine and triethylamine.
  • Ammonium salts of an inorganic acid include ammonium chloride, ammonium bromide, ammonium sulfate, ammonium phosphate and ammonium nitrate.
  • Inorganic acid salts include hydrochlorides, hydrobromides, sulfates, hydroiodides and nitrates.
  • Reaction scheme 1 of the present invention illustrates the process of preparing 6-chloro-5- ⁇ 2,6-difluoro-4-[3-(methylamino)propoxy]phenyl ⁇ -2-pyrazin-2-yl-
  • step a pyrazine-2-carbonitrile 1 is reacted in an alcohol solvent, preferably methyl alcohol in the presence of base A selected from an alkali metal hydroxide or alkali metal alkoxide, preferably sodium methoxide and more preferably sodium methoxide in a ratio of about 1:1 (mole/mole) in the temperature range of about 20 - 40 0 C, preferably in the range of about 28 - 32 0 C for about 3 - 12 h, preferably in the range of 4 - 5 h, followed by treating with an ammonium salt of an inorganic acid, for example, ammonium chloride for a period of about 16 - 48 h, preferably in the range of 20 - 24 h at about 25 0 C or optionally for about 3-6 h at reflux.
  • base A selected from an alkali metal hydroxide or alkali metal alkoxide, preferably sodium methoxide and more preferably sodium methoxide in a ratio of about 1:1 (mole/mole
  • Methyl f-butyl ether is added and the mixture is stirred for about 15 to 30 min and the solid which forms is collected by filtration, washed with methyl t- butyl ether then dried at about 4O 0 C under vacuum to give pyrazine-2-carboxamidine hydrochloride 2 as a white solid.
  • the volatiles are removed to a residue and the residue is crystallized from ethanol-diethyl ether and the product collected.
  • the procedure described has higher yields as compared to the art (S. Kushner et al, J. Amer. Chem. Soc, 74, 3617-3621 (1952) and published patent application US2005-0075357A1).
  • step b 2-(2,4,6-trifluoro-phenyl)-malonic acid diester 3 wherein R 1 and R 2 are independently alkyl of 1 to 3 carbon atoms, preferably ethyl is reacted with pyrazine-2-carboxamidine hydrochloride 2 in a ratio of about 1:1 to 1 :1.5 mole/mole, preferably in the range of 1:1.2 mole/mole in the presence of a base selected from an alkali metal hydroxide, alkali metal carbonate, and an alkali metal hydride or optionally an amine base selected from 1 ,8-diazabicyclo[4.3.0]non-5- ene(DBU), N,N-diisopropylethylamine and triethylamine in an aprotic solvent to form the 2-pyrazin-2-yl-5-(2,4,6-trifluoro-phenyl)-pyrimidine-4,6-diol 4.
  • a base selected from an al
  • the base is an alkali metal carbonate.
  • the base is potassium carbonate in a ratio of 1:1.2 mole/mole in diglyme or alternatively a ratio of 1:2 mole/mole for DBU in 1-methyl-2-pyrrolidinone (NMP).
  • the aprotic solvent is selected from N,N-dimethylformamide, 1- methyl-2-pyrrolidinone (NMP) and 2-methoxyethyl ether (diglyme), more preferably, diglyme and NMP, at a temperature range of about 80° to 180 0 C, preferably 120 - 140 0 C in diglyme with potassium carbonate and preferably about 95 0 C in NMP with DBL ) for about 3 - 1O h, preferably in the range of 4 - 6 h to form the 2-pyrazin-2-yl-5- (2,4,6-trifluoro-phenyl)-pyrimidine-4,6-diol 4.
  • NMP 1- methyl-2-pyrrolidinone
  • diglyme 2-methoxyethyl ether
  • the reaction mixture in diglyme with potassium carbonate is cooled to 25 - 30 0 C, water is added, followed by the addition of acetic acid followed by aqueous HCI or other mineral acid to a pH of about 1 - 3, preferably about 2-3 forming a solid which is filtered, washed with water and optionally washed with isopropyl alcohol respectively.
  • the solid is dried at about 60 °C/0-10 mmHg for about 24 h to give 2-pyrazin-2-yl-5-(2,4,6-trifluoro-phenyl)- pyrimidine-4,6-diol 4 as a solid which is used directly for the next step.
  • reaction mixture under the alternative conditions of amine base DBU with aprotic solvent NMP is cooled to about 50 0 C and aqueous HCI is added forming a solid, which is filtered and washed with water.
  • the solid is dried at about 60 °C/0-10 mmHg for about 24 h to give 2-pyrazin-2-yl-5-(2,4,6-trifluoro-phenyl)-pyrimidine-4,6- diol 4 as a solid which is used directly for the next step.
  • step c to a mixture of 2-pyrazin-2-yl-5-(2,4,6- trifluoro-phenyl)-pyrimidine-4,6-dio! 4 in an aprotic solvent preferably toluene (g/ml) preferably 5-15 parts, more preferably in 5 - 10 parts, most preferable in 7 parts, is slowly added at about 10-15 0 C, phosphorus oxychloride.
  • an aprotic solvent preferably toluene (g/ml) preferably 5-15 parts, more preferably in 5 - 10 parts, most preferable in 7 parts
  • N,N-diisopropylethyl amine in a molar ratio of about 1 :1 to 1:5, preferably in the range of 1 :4 is slowly added at about 10-15 0 C and the mixture heated to reflux for about 6 to 24 h, preferably about 6 h.
  • the volatiles are removed by distillation to a residue which is further distilled with toluene preferably two times to afford a further residue.
  • the further residue is dissolved in a solvent selected from ethyl acetate, dichloromethane and toluene, preferably ethyl acetate then partitioned by pouring into water while maintaining the temperature between about 5 - 15° C.
  • the solvent layer is separated, washed with water, dried over sodium sulfate and filtered through a pad of filter aid such as diatomaceous earth or through hydrous magnesium silicate and most of the volatiles removed to a residue to which is added heptane forming a precipitated product.
  • the precipitated product 4,6-dichloro-2-pyrazin-2-yl-5-(2,4,6-trifluoro-phenyl)-pyrimidine 5 is collected and having a purity of >95% as shown by high pressure liquid chromatography
  • step d a solution of 4, 6-dichloro-2-pyrazin-2-yl-5-(2,4,6- trifluoro-phenyl)-pyrimidine 5 in an aprotic solvent, preferably 1-methyl-2- pyrrolidinone (NMP) in a ratio of 1 - 10 mL NMP/g of 4, 6-dichloro-2-pyrazin-2-yl-5- (2,4,6-trifluoro-phenyl)-pyrimidine 5, preferably 1 - 5 mL NMP/g of 4, 6-dichloro-2- pyrazin-2-yl-5-(2,4,6-trifluoro-phenyl)-pyrimidine 5, most preferably 1 mL NMP/g of 4, 6-dichloro-2-pyrazin-2-yl-5-(2,4,6-trifluoro-phenyl)-pyrimidine 5 is added (S)-2,2,2- trifluoro-1-methyl-ethylamine 6 in a mole ratio of
  • the reaction is sealed to prevent loss of (S)-2,2,2-trifluoro-1-methyl-ethylamine 6.
  • the reaction mixture is diluted with isopropyl alcohol (IPA), IPA to NMP (VA/) of about 1:1-1:5 preferable at about 1 :3, then water is added with stirring at about 10 - 20 0 C in a ratio of NMP to water (v/v) of about 1:1 - 1 :5 (v/v), preferably at about 1 :3 (v/v) with about 30 minutes of additional stirring and collecting, without the need of chromatography, the solid product, washing with water and drying to give 6-chloro-2-pyrazin-2-yl-N- [(1S)-2,2,2-trifluoro-1-methylethyl]-5-(2,4,6-trifluorophenyl)pyrimidin-4-amine 7.
  • step e to a solution of a base B selected from alkali metal alkoxide preferably potassium t-butoxide or a suspension of alkali metal hydride preferably sodium hydride (60% in mineral oil) in an aprotic solvent preferably anhydrous tetrahydrofuran (THF), optionally dimethylsulfoxide (DMSO) is added amino alcohol HO-(CH 2 J 3 -N HCH 3 dropwise at a temperature range of about 10 - 40 0 C preferably at about 23 0 C for about 30 minutes wherein the ratio of aprotic solvent to aminoalcohol is preferably about 5 mL THF/g of aminoalcohol HO-(CH 2 ) 3 -NHCH 3 .
  • a base B selected from alkali metal alkoxide preferably potassium t-butoxide or a suspension of alkali metal hydride preferably sodium hydride (60% in mineral oil) in an aprotic solvent preferably anhydrous tetrahydrofuran
  • the mixture is stirred at 23 ⁇ 2 0 C for about 18 - 4O h, preferably about 24 h.
  • the reaction mixture is added to cold water at about 5 - 15 0 C, preferably about 10 0 C, in a ratio of water to 6-chloro-2-pyrazin-2-yl-N-[(1 S)-2,2,2-trifluoro-1- methylethyl]-5-(2,4,6-trifluorophenyl)pyrimidin-4-amine 7 of about 14 mL/g.
  • step f a solution of fumaric acid in ethanol is added to the organic phase preferably ethyl acetate in a more preferred ratio of 1 :1 (V/V) to give the pharmaceutically acceptable hemifumarate salt which is collected.
  • the overall yield is 80-90% with a purity of -98% HPLC.
  • steps e and f may be combined in a single step.
  • composition which comprises ⁇ -chloro-S ⁇ .e-difluoro ⁇ -fS-CmethylaminoJpropoxylphenyl ⁇ -pyrazin ⁇ -yl- N-[(1S)-2,2,2-trifluoro-1-methylethyl]pyrimidin-4-amine hemifumarate in association or combination with a pharmaceutically acceptable carrier.
  • this invention provides a method of treating, inhibiting the growth of, or eradicating a tumor in a mammal in need thereof, wherein said tumor is resistant to at least one chemotherapeutic agent, which comprises administering to said mammal an effective amount of 6-chloro-5- ⁇ 2,6-difluoro-4-[3-(methylamino)propoxy]phenyl ⁇ -2-pyrazin-2-yl- N-[(1S)-2,2,2-trifluoro-1-methylethyl]pyrimidin-4-amine hemifumarate.
  • the effective dosage of 6-chloro-5- ⁇ 2,6-difluoro-4-[3- (methylamino)propoxy]phenyl ⁇ -2-pyrazin-2-yl-N-[(1S)-2,2,2-trifluoro-1- methylethyl]pyrimidin-4-amine hemifumarate employed may vary depending on the mode of administration and severity of the condition being treated. However, in general satisfactory results are obtained when administered in amounts ranging from about 0.10 to about 100 mg/kg of body weight per day.
  • a preferred regimen for optimum results would be from about 1 mg to about 20 mg/kg of body weight per day and such dosage units are employed that a total of from about 70 mg to about 1400 mg of 6-chloro-5- ⁇ 2,6-difluoro-4-[3-(methylamino)propoxy]phenyl ⁇ -2-pyrazin-2- yl-N-[(1 S)-2,2,2-trifluoro-1 -methylethyl]pyrimidin-4-amine hemifumarate for a human subject of about 70 kg of body weight are administered in a 24 hour period.
  • the dosage regimen may be adjusted to provide the optimum therapeutic response. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation.
  • a decidedly practical advantage is that 6-chloro-5- ⁇ 2,6-difluoro-4-[3- (methylaminoJpropoxylphenylJ ⁇ -pyrazin ⁇ -yl-N-KISJ ⁇ -trifluoro-i- methylethyl]pyrimidin-4-amine hemifumarate may be administered in any convenient manner such as by the oral, intravenous, intramuscular or subcutaneous routes.
  • the 6-chloro-5- ⁇ 2,6-difluoro-4-[3-(methylamino)propoxy]phenyl ⁇ -2-pyrazin-2-yl-N- [(1S)-2,2,2-trifluoro-1-methylethyl]pyrimidin-4-amine hemifumarate may be orally administered, for example, with an inert diluent or with an assimilable edible carrier, or they may be enclosed in hard or soft shell gelatin capsules, or may be compressed into tablets or they may be incorporated directly with the food of the diet.
  • 6-chloro-5- ⁇ 2,6-difluoro-4-[3- (methylamino)propoxy]phenyl ⁇ -2-pyrazin-2-yl-N-[(1S)-2,2,2-trifluoro-1- methylethyl]pyrimidin-4-amine hemifumarate may be incorporated with excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers and the like.
  • compositions and preparations should contain at least 0.1% of 6-chloro-5- ⁇ 2,6-difluoro-4-[3- (methylamino)propoxy]phenyl ⁇ -2-pyrazin-2-yl-N-[(1S)-2,2,2-trifluoro-1- rnethylethyl]pyrimidin-4-amine hemifumarate.
  • the percentage of the compositions and preparations may, of course, be varied and may conveniently be between about 2% to about 60% of the weight of the unit.
  • compositions or preparations according to the present invention are prepared so that an oral dosage unit form contains between 10 and 1000 mg of 6-chloro-5- ⁇ 2,6-difluoro-4-[3-
  • the tablets, troches, pills, capsules and the like may also contain the following: a binder such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, lactose, or saccharin may be added or a flavoring agnet such as peppermint, oil of wintergreen or cherry flavoring.
  • a binder such as gum tragacanth, acacia, corn starch or gelatin
  • excipients such as dicalcium phosphate
  • a disintegrating agent such as corn starch, potato starch, alginic acid and the like
  • a lubricant such as magnesium stearate
  • a sweetening agent such as sucrose, lactose, or saccharin may be added or a flavoring agne
  • tablets, pills or capsules may be coated with shellac, sugar or both.
  • a syrup or elixir may contain 6-chloro-5- ⁇ 2,6- difluoro-4-[3-(methyiamino)propoxy]phenyl ⁇ -2-pyrazin-2-yl-N-[(1S)-2,2,2-trifluoro-1- methylethyl]pyrimidin-4-amine hemifumarate, sucrose, as a sweetening agent, methyl and propylparabens as preservatives, a dye and flavoring such as cherry or orange flavor.
  • any material used in preparing any dosage unit form should be pharmaceutically pure and substantially non-toxic in the amounts used.
  • 6-Chloro-5- ⁇ 2,6-difluoro-4-[3-(methylamino)propoxy]phenyl ⁇ -2-pyrazin-2-yl-N- [(1S)-2,2,2-trifluoro-1-methylethyl]pyrimidin-4-amine hemifumarate may also be administered parenterally or intraperitoneally.
  • Solutions or suspensions can be prepared in water suitably mixed with a surfactant such as hydroxypropylcellulose.
  • Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth or microorganisms.
  • the pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions.
  • the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be prepared against the contaminating action of microorganisms such as bacteria and fungi.
  • the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol and liquid poly-ethyiene glycol), suitable mixtures thereof, and vegetable oils.
  • Intravenous administration is a preferred manner of administration of 6- chloro-5- ⁇ 2,6-difluoro-4-[3-(methylamino)propoxy]phenyl ⁇ -2-pyrazin-2-yl-N-[(1S)- 2,2,2-trifluoro-1-methylethyl]pyrimidin-4-amine hemifumarate.
  • suitable carriers include physiological saline, bacteriostatic water, Cremophor ELTM (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS).
  • the composition must be sterile and should be fluid to the extent that easy syringability exists.
  • the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyetheylene glycol, and the like), and suitable mixtures thereof.
  • polyol for example, glycerol, propylene glycol, and liquid polyetheylene glycol, and the like
  • Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like.
  • isotonic agents for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition.
  • Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.
  • a mixture of 2-(2,4,6-trifluoro-phenyl)-malonic acid diethyl ester (200 g, 0.67 mol), pyrazine-2-carboxamidine hydrochloride (132 g, 0.828 mol) and potassium carbonate (114 g, 0.828 mol) in 2-methyoxyethyl ether (diglyme, 600 mL) is heated to 120 0 C and stirred for 4 h, then heated to 140 °C and stirred for an additional 2 h.
  • the mixture is cooled to room temperature (25-30° C) and water (1200 mL) is added over about 15 min.
  • Acetic acid (50 g) is added over 15 min.
  • the mixture is cooled to about 50 0 C and then HCI solution (37%, 5.6 mL) is added dropwise, keeping the temperature below 50 0 C.
  • the mixture is then allowed to cool to about 20 0 C.
  • Water (50 mL) is added dropwise over 20 minutes, causing the product to precipitate as a solid from the mixture (20-25° C).
  • the solid is collected by filtration, and the product cake is washed with water (300 mL).
  • the solid is allowed to dry at 23 0 C under atmospheric pressure for 24 hours, giving a yellow solid (11.5 g, 97% HPLC area, 76% yield.
  • reaction mixture is cooled to room temperature and diluted with IPA (120 mL) and water (120 mL) added slowly over 30 minutes to form a solid.
  • the solid is filtered and washed with water (2x60 mL) to give 6-chloro-2-pyrazin-2-yl-N- [(1S)-2,2,2-trifluoro-1-methylethyl]-5-(2,4 I 6-trifluorophenyl)pyrimidin-4-amine in 84% yield and having a 98% HPLC purity and an enantiomeric excess of >99%.
  • NMR indicates the ratio of acid to base is 0.5 to 1.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne 6-chloro-5-{2,6-difluoro-4-[3-(méthylamino)propoxy]phényl}-2-pyrazin-2-yl-N-[(1S)-2,2,2-trifluoro-1-méthyléthyl]pyrimidin-4-amine hémifumarate représentant un inhibiteur de tubuline utile pour le traitement du cancer, ainsi que des méthodes servant à préparer ledit hémifumarate.
EP06784720A 2005-06-13 2006-06-08 Inhibiteur de tubuline et sa methode de preparation Withdrawn EP1891052A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US69001605P 2005-06-13 2005-06-13
US80278106P 2006-05-24 2006-05-24
PCT/US2006/022574 WO2006138180A1 (fr) 2005-06-13 2006-06-08 Inhibiteur de tubuline et sa methode de preparation

Publications (1)

Publication Number Publication Date
EP1891052A1 true EP1891052A1 (fr) 2008-02-27

Family

ID=37074929

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06784720A Withdrawn EP1891052A1 (fr) 2005-06-13 2006-06-08 Inhibiteur de tubuline et sa methode de preparation

Country Status (12)

Country Link
EP (1) EP1891052A1 (fr)
JP (1) JP2008543838A (fr)
AR (1) AR054392A1 (fr)
AU (1) AU2006259663A1 (fr)
BR (1) BRPI0612145A2 (fr)
CA (1) CA2610416A1 (fr)
GT (1) GT200600257A (fr)
MX (1) MX2007015718A (fr)
PE (1) PE20070114A1 (fr)
SV (1) SV2007002573A (fr)
TW (1) TW200716613A (fr)
WO (1) WO2006138180A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2581207T3 (es) 2009-11-12 2016-09-02 Tube Pharmaceuticals Gmbh Inhibidores de la tubulina
EP2903436B1 (fr) * 2012-09-19 2019-07-17 The Trustees Of The University Of Pennsylvania Composés hétérocycliques et leur utilisation pour le traitement de tauopathies neurodégénératives
WO2017181974A1 (fr) * 2016-04-20 2017-10-26 苏州苏领生物医药有限公司 Composé hétérocyclique à cinq chaînons, procédé de préparation correspondant, composition pharmaceutique et utilisation
EP3758696B1 (fr) 2018-03-02 2026-02-25 The Trustees of the University of Pennsylvania Composés de [1,2,4]triazolo[1,5-a]pyrimidine et utilisation de ces derniers dans la stabilisation de microtubules

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1680425T1 (sl) * 2003-09-24 2007-04-30 Wyeth Corp 6-((substituirani)fenil)triazolopirimidini kot sredstva proti raku
JP2007506746A (ja) * 2003-09-24 2007-03-22 ワイス・ホールディングズ・コーポレイション 抗癌剤としての５−アリールピリミジン類

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2006138180A1 *

Also Published As

Publication number Publication date
MX2007015718A (es) 2008-02-21
GT200600257A (es) 2007-02-14
AR054392A1 (es) 2007-06-20
JP2008543838A (ja) 2008-12-04
AU2006259663A1 (en) 2006-12-28
CA2610416A1 (fr) 2006-12-28
BRPI0612145A2 (pt) 2010-10-19
WO2006138180A1 (fr) 2006-12-28
SV2007002573A (es) 2007-01-03
TW200716613A (en) 2007-05-01
PE20070114A1 (es) 2007-02-03

Similar Documents

Publication Publication Date Title
US4923986A (en) Derivatives of physiologically active substance K-252
US5856481A (en) 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative
US12577233B2 (en) Solid forms of APOL1 inhibitor and methods of using same
JPH11269146A (ja) 分化誘導剤
CN117120051A (zh) 甲状腺激素受体β激动剂化合物
US7501423B2 (en) Tubulin inhibitor and process for its preparation
EP2889287B1 (fr) Dérivé de dolastatine-10, procédé pour le produire et composition de médicament anticancéreux le contenant
US20240327438A1 (en) Prodrugs of stat3 inhibitors
KR20060098368A (ko) 항암제로서의 6-[(치환된)페닐]트리아졸로피리미딘
EP1891052A1 (fr) Inhibiteur de tubuline et sa methode de preparation
CN108794517B (zh) 一种精氨酸酶抑制剂及其制备方法与用途
US11964987B2 (en) Isoidide derivatives and methods of making and using same
US7396835B2 (en) Process for the preparation of tubulin inhibitors
US20210380558A1 (en) Beta-catenin and b-cell lymphoma 9 (bcl9) inhibitors
US20250082657A1 (en) Conjugates of chemotherapy agents and tissue-binding small molecules, compositions and methods thereof
CN113557236A (zh) 一种双功能免疫调节剂及其在药学上可接受的盐、药物组合物
US10471154B2 (en) Spirocyclic indolone polyethylene glycol carbonate compound, composition, preparation method and use thereof
TWI893772B (zh) 作為tyk2抑制劑的雜環化合物及合成與應用
US10617706B2 (en) Compounds for cancer chemotherapeutic sensitization
US20250346616A1 (en) Rock inhibitors and uses thereof
EA052543B1 (ru) Пролекарства ингибиторов stat3
CN113354590A (zh) 拮抗nod1/2受体信号通路的喹唑啉酮类化合物
CN114085214A (zh) 索凡替尼杂质及其制备方法和用途
WO2019047686A1 (fr) Composés de cyclobutyle-imidazolidinone
HK1165216A (en) Process for the preparation of alogliptin

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20071128

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20080630

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: WYETH LLC

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110302